Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of myasthenia gravis. Disclosures: Anthony Béhin is a consultant for Alexion, Argenx, UCB, Sanofi and Ultragenyx pharmaceutical. He has received grant/research support from the Association Institut de Myologie and is on the […]

Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses his abstract on the safety profile of anti-FcRn drugs, in particular efgartigimod, and anti-complement drugs in the treatment of IgG-mediated autoimmune diseases. The abstract ‘EPR-128 Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases’ was presented at the annual European Academy […]

Prof. Elon Eisenberg (Tachnion – Israel Institute of Technology, Haifa, Israel) summarizes our current knowledge on using cannabis in pain medicine, and the unmet needs in this field. He then provides some practical advice on using cannabis in clinical practice and offers his perspective on the next steps and what further studies are required. The […]

Dr Luca Leonardi (Sapienza University of Rome, Italy) summarizes the take-home messages from his study assessing skin biopsy as a marker of disease onset and severity in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a treatable disease. The abstract ‘EJoN: Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary […]

touchNEUROLOGY editorial board member Prof. Angelo Antonini (Padua University Hospital, Italy) provides an overview of his top three most important updates and hot topics from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of Parkinson’s disease. He particularly focusses on new insights in early detection of the disease before motor symptoms […]

In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a new potential biomarker of visual snow syndrome, and the second a presentation that he […]

In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of headache disorders. He highlights two important presentations using calcitonin gene-related peptide […]

Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]

Muscle-specific kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) is usually more clinically severe than acetylcholine receptor autoantibody-positive (AChR-Ab+) gMG. The Phase 3 MycarinG study analysed rozanolixizumab in patients with AChR-Ab+ or MuSKAb+ gMG. Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes the take-home messages from her presentation of the results of the study. The […]

Dr Sabrina Sacconi (Côte d’Azur University, Nice, France) summarizes her top 3 highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of myasthenia gravis, an area with significant unmet needs for treatment options. It is an exciting time for research in this area, with a number of important clinical trials […]

Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) summarizes some of the key updates to the EAN guidelines, and the take-home messages presented at the annual European Academy of Neurology (EAN), July 1–4, 2023. Disclosures: Kristian Steen Frederiksen has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming was supported by Touch […]

Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) discusses his highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of Alzheimer’s disease and dementia. Disclosures:Kristian Steen Frederiksen has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson. […]

Data emerging from upcoming clinical trials assessing the treatment efficacy in people with clinically established Parkinson’s disease will shed light on optimal treatment approaches. In this interview with touchNEUROLOGY, Prof. Angelo Antonini (IRCCS San Camillo, Venice, and University of Padova, Italy) gives his thoughts on these and discusses how new efficacious therapies for Parkinson’s disease […]

Slowing down the progression of Parkinson’s disease is key to improving outcomes. In this interview with touchNEUROLOGY, Prof. Angelo Antonini (IRCCS San Camillo, Venice, and University of Padova, Italy) presents the core concept of the Movement Disorders Society Task Force on the biological definition of Parkinson’s disease and treatment objectives, and shares his thoughts on […]

Huntingtin (HTT) is a gene containing a key region of CAG repeats. Dr Salvatore Mazzeo (University of Florence, Florence, Italy) discusses his study on HTT alleles containing from 27 to 35 CAG repeats – termed intermediate alleles (IAs) – and the effect of these IAs on progression of cognitive impairment in patients with subjective cognitive […]

In this touchNEUROLOGY interview at EAN 2022, Dr Salvatore Mazzeo (University of Florence, Florence, Italy) discusses his study on HTT alleles containing from 27 to 35 CAG repeats – termed intermediate alleles (IAs) – and the effect of these IAs on progression of cognitive impairment in patients with subjective cognitive decline. The abstract titled, Huntingtin […]

Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors and outcomes in MS and related disorders. Questions:  How does cognitive impairment predict physical […]